BIOMARIN PHARMACEUTICAL INC — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 45/100
What the filing says
BioMarin Pharmaceutical Inc. (purchaser) is acquiring 100% of Alesta Therapeutics B.V. (Company) from multiple sellers for $275 million in upfront consideration, plus Cash and Cash Equivalents retained, minus Indebtedness and transaction expenses, plus up to $215 million in contingent milestone payments tied to development and regulatory approval of ALE-1 (lead candidate for hypophosphatasia). The deal includes a spin-out of certain assets to SpinCo and a 1cBio equity investment transaction. Closing is expected within 90 days of satisfaction of conditions.
Why this rating
Moderate acquisition: $275M upfront is ~4% of BioMarin's $6.7B market cap; highly contingent on undisclosed milestones. Early-stage asset adds diversification but typical for biotech M&A; manageable relative to company size.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.